Loading...

FDA Remediation And Genome Valley Ramp-Up Will Unlock Capacity

Published
17 Feb 25
Updated
27 Aug 25
AnalystConsensusTarget's Fair Value
₹573.71
4.3% undervalued intrinsic discount
04 Sep
₹549.20
Loading
1Y
-4.2%
7D
1.4%

Author's Valuation

₹573.714.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on27 Aug 25
Fair value Decreased 4.83%

The slight downward revision in Granules India’s consensus price target to ₹573.71 reflects marginally lower future P/E and revenue growth forecasts. What's in the News Dr. Kandiraju Venkata Sitaram Rao will resign as CEO of Granules India, effective at the close of business on July 31, 2025.

Shared on01 May 25
Fair value Decreased 5.02%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 2.03%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 0.49%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Increased 5.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.